Positive Group Stock

Equities

POSI

RU000A103X66

Software

End-of-day quote Moscow Micex - RTS 06:00:00 2022-07-07 pm EDT 5-day change 1st Jan Change
869.6 RUB +0.65% Intraday chart for Positive Group -.--% -.--%
Sales 2022 13.77B 149M Sales 2023 22.21B 241M Capitalization 57.39B 622M
Net income 2022 6.09B 65.95M Net income 2023 9.7B 105M EV / Sales 2022 4.22 x
Net Debt 2022 675M 7.31M Net Debt 2023 3.99B 43.26M EV / Sales 2023 2.76 x
P/E ratio 2022
9.43 x
P/E ratio 2023
5.92 x
Employees 2,285
Yield 2022
6.6%
Yield 2023
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Public Joint Stock Company Positive Group Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Public Joint Stock Company Positive Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Public Joint Stock Company Positive Group Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Public Joint Stock Company Positive Group Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Public Joint Stock Company Positive Group Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Certain Ordinary Shares of Public Joint Stock Company Positive Group are subject to a Lock-Up Agreement Ending on 29-MAR-2023. CI
Transcript : PropertyGuru Limited, Q1 2022 Earnings Call, May 26, 2022
Transcript : AcadeMedia AB, Q3 2022 Earnings Call, May 05, 2022
Draftkings Positive Group Dynamics Supports Long-term Margin Targets if More States Legalize Gambling, Oppenheimer Says MT
Transcript : The Hongkong and Shanghai Hotels, Limited, 2021 Earnings Call, Mar 16, 2022
Transcript : Fraport AG, 2021 Earnings Call, Mar 15, 2022
Transcript : Gresham Technologies plc, 2021 Earnings Call, Mar 08, 2022
Transcript : Delivery Hero SE, Q4 2021 Sales/ Trading Statement Call, Feb 10, 2022
Transcript : Prometheus Biosciences, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-09-2021 04:20 PM
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma CI
More news
3 years
405.00
Extreme 405
1 350.00
5 years
405.00
Extreme 405
1 350.00
10 years
405.00
Extreme 405
1 350.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 39 21-07-29
Founder 46 97-12-31
Director of Finance/CFO - 18-12-31
Members of the board TitleAgeSince
Corporate Officer/Principal 48 17-09-26
Director/Board Member - 21-12-05
Founder 46 97-12-31
More insiders
Gruppa Pozitiv PAO is a Russia-based company primarily engaged in software development activities. The Company develops, markets and supports a range of IT security software products and services that identify, verify and mitigate real business risks that may arise in an enterprise's IT infrastructure. The Company provides a number of services in the field of cybersecurity, including continuous analysis of business security, detection, response and investigation of complex incidents, monitoring the security of corporate systems. Also, the Company develops educational programs for universities.
More about the company